epsilon-Polylysine-Capped Mesoporous Silica Nanoparticles as Carrier of the C9h Peptide to Induce Apoptosis in Cancer Cells

[EN] Apoptotic signaling pathways are altered in numerous pathologies such as cancer. In this scenario, caspase-9/PP2Ac alpha interaction constitutes a key target with pharmacological interest to re-establish apoptosis in tumor cells. Very recently, a short peptide (C9h) known to disrupt caspase-9/PP2Ac alpha interaction with subsequent apoptosis induction was described. Here, we prepared two sets of mesoporous silica nanoparticles loaded with safraninO (S2) or with C9h peptide (S4) and functionalized with epsilon-polylysine as capping unit. Aqueous suspensions of both nanoparticles showed negligible cargo release whereas in the presence of pronase, a marked delivery of safraninO or C9h was observed. Confocal microscopy studies carried out with HeLa cells indicated that both materials were internalized and were able to release their entrapped cargos. Besides, a marked decrease in HeLa cell viability (ca. 50%) was observed when treated with C9h-loaded S4 nanoparticles. Moreover, S4 provides peptide protection from degradation additionally allowing for a dose reduction to observe an apoptotic effect when compared with C9h alone or in combination with a cell-penetrating peptide (i.e., Mut3DPT-C9h). Flow cytometry studies, by means of Annexin V-FITC staining, showed the activation of apoptotic pathways in HeLa as a consequence of S4 internalization, release of C9h peptide and disruption of caspase-9/PP2Ac alpha interaction.The authors wish to express their gratitude to the Spanish government (Projects MAT2015-64139-C4-1, SAF2012-31405, SAF2015-67077-R, AGL2015-70235-C2-2-R (MINECO/FEDER)), the Generalitat Valencia (Projects PROMETEOII/2014/047, PROMETEO/2012/061) and the CIBER-BBN for their support. C.T. is grateful to the Spanish Ministry of Science and Innovation for her Ph.D. fellowship.De La Torre-Paredes, C.; Domínguez-Berrocal, L.; Murguía, JR.; Marcos Martínez, MD.; Martínez-Máñez, R.; Bravo, J.; Sancenón Galarza, F. (2018). epsilon-Polylysine-Capped Mesoporous Silica Nanoparticles as Carrier of the C9h Peptide to Induce Apoptosis in Cancer Cells. Chemistry - A European Journal. 24(8):1890-1897. https://doi.org/10.1002/chem.201704161S18901897248Lyon, M. A., Ducruet, A. P., Wipf, P., & Lazo, J. S. (2002). Dual-specificity phosphatases as targets for antineoplastic agents. Nature Reviews Drug Discovery, 1(12), 961-976. doi:10.1038/nrd963Ducret, F., Turc-Baron, C., Pointet, P., Vernin, G., Skowron, O., Mc Gregor, B., … Vincent, M. (2005). Tumeur à rénine. À propos d’un nouveau cas diagnostiqué au cours d’une grossesse. Néphrologie & Thérapeutique, 1(1), 52-61. doi:10.1016/j.nephro.2005.01.008Lazar, D. F., & Saltiel, A. R. (2006). Lipid phosphatases as drug discovery targets for type 2 diabetes. Nature Reviews Drug Discovery, 5(4), 333-342. doi:10.1038/nrd2007Tonks, N. K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nature Reviews Molecular Cell Biology, 7(11), 833-846. doi:10.1038/nrm2039Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991). Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66(4), 807-815. doi:10.1016/0092-8674(91)90124-hLi, Y. M., & Casida, J. E. (1992). Cantharidin-binding protein: identification as protein phosphatase 2A. Proceedings of the National Academy of Sciences, 89(24), 11867-11870. doi:10.1073/pnas.89.24.11867Honkanen, R. E. (1993). Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS Letters, 330(3), 283-286. doi:10.1016/0014-5793(93)80889-3Walsh, A. H., Cheng, A., & Honkanen, R. E. (1997). Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A. FEBS Letters, 416(3), 230-234. doi:10.1016/s0014-5793(97)01210-6Medyouf, H., Alcalde, H., Berthier, C., Guillemin, M. C., dos Santos, N. R., Janin, A., … Ghysdael, J. (2007). Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nature Medicine, 13(6), 736-741. doi:10.1038/nm1588Martinez-Martinez, S., & Redondo, J. (2004). Inhibitors of the Calcineurin / NFAT Pathway. Current Medicinal Chemistry, 11(8), 997-1007. doi:10.2174/0929867043455576Arrouss, I., Nemati, F., Roncal, F., Wislez, M., Dorgham, K., Vallerand, D., … Rebollo, A. (2013). Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy. PLoS ONE, 8(4), e60816. doi:10.1371/journal.pone.0060816Arrouss, I., Decaudin, D., Choquet, S., Azar, N., Parizot, C., Zini, J., … Rebollo, A. (2015). Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia. Protein & Peptide Letters, 22(6), 539-546. doi:10.2174/0929866522666150216115352Fominaya, J., Bravo, J., & Rebollo, A. (2015). Strategies to stabilize cell penetrating peptides forin vivoapplications. Therapeutic Delivery, 6(10), 1171-1194. doi:10.4155/tde.15.51Fominaya, J., Bravo, J., Decaudin, D., Brossa, J. Y., Nemati, F., & Rebollo, A. (2015). Enhanced serum proteolysis resistance of cell-penetrating peptides. Therapeutic Delivery, 6(2), 139-147. doi:10.4155/tde.14.100Primeau, A. J. (2005). The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors. Clinical Cancer Research, 11(24), 8782-8788. doi:10.1158/1078-0432.ccr-05-1664Izquierdo, M. A., Shoemaker, R. H., Flens, M. J., Scheffer, G. L., Wu, L., Prather, T. R., & Scheper, R. J. (1996). Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. International Journal of Cancer, 65(2), 230-237. doi:10.1002/(sici)1097-0215(19960117)65:23.0.co;2-hLiang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2009). Circumventing Tumor Resistance to Chemotherapy by Nanotechnology. Multi-Drug Resistance in Cancer, 467-488. doi:10.1007/978-1-60761-416-6_21He, Q., & Shi, J. (2013). MSN Anti-Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition. Advanced Materials, 26(3), 391-411. doi:10.1002/adma.201303123Ding, C., & Li, Z. (2017). A review of drug release mechanisms from nanocarrier systems. Materials Science and Engineering: C, 76, 1440-1453. doi:10.1016/j.msec.2017.03.130Llopis-Lorente, A., Lozano-Torres, B., Bernardos, A., Martínez-Máñez, R., & Sancenón, F. (2017). Mesoporous silica materials for controlled delivery based on enzymes. Journal of Materials Chemistry B, 5(17), 3069-3083. doi:10.1039/c7tb00348jTibbitt, M. W., Dahlman, J. E., & Langer, R. (2016). Emerging Frontiers in Drug Delivery. Journal of the American Chemical Society, 138(3), 704-717. doi:10.1021/jacs.5b09974Mai, W. X., & Meng, H. (2012). Mesoporous silica nanoparticles: A multifunctional nano therapeutic system. Integrative Biology, 5(1), 19-28. doi:10.1039/c2ib20137bDoadrio, A., Salinas, A., Sánchez-Montero, J., & Vallet-Regí, M. (2015). Drug release from ordered mesoporous silicas. Current Pharmaceutical Design, 21(42), 6213-6819. doi:10.2174/1381612822666151106121419Argyo, C., Weiss, V., Bräuchle, C., & Bein, T. (2013). Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery. Chemistry of Materials, 26(1), 435-451. doi:10.1021/cm402592tGagliardi, M. (2017). Recent Advances in Preclinical Studies and Potential Applications of Dendrimers as Drug Carriers in the Central Nervous System. Current Pharmaceutical Design, 23(21). doi:10.2174/1381612823666170313124811Zhang, R. X., Ahmed, T., Li, L. Y., Li, J., Abbasi, A. Z., & Wu, X. Y. (2017). Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. Nanoscale, 9(4), 1334-1355. doi:10.1039/c6nr08486aGuo, X., Wang, L., Wei, X., & Zhou, S. (2016). Polymer-based drug delivery systems for cancer treatment. Journal of Polymer Science Part A: Polymer Chemistry, 54(22), 3525-3550. doi:10.1002/pola.28252Li, Z., Barnes, J. C., Bosoy, A., Stoddart, J. F., & Zink, J. I. (2012). Mesoporous silica nanoparticles in biomedical applications. Chemical Society Reviews, 41(7), 2590. doi:10.1039/c1cs15246gWang, Y., Zhao, Q., Han, N., Bai, L., Li, J., Liu, J., … Wang, S. (2015). Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine: Nanotechnology, Biology and Medicine, 11(2), 313-327. doi:10.1016/j.nano.2014.09.014Sun, R., Wang, W., Wen, Y., & Zhang, X. (2015). Recent Advance on Mesoporous Silica Nanoparticles-Based Controlled Release System: Intelligent Switches Open up New Horizon. Nanomaterials, 5(4), 2019-2053. doi:10.3390/nano5042019Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991-1003. doi:10.1038/nmat3776Tarn, D., Ashley, C. E., Xue, M., Carnes, E. C., Zink, J. I., & Brinker, C. J. (2013). Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility. Accounts of Chemical Research, 46(3), 792-801. doi:10.1021/ar3000986Aznar, E., Oroval, M., Pascual, L., Murguía, J. R., Martínez-Máñez, R., & Sancenón, F. (2016). Gated Materials for On-Command Release of Guest Molecules. Chemical Reviews, 116(2), 561-718. doi:10.1021/acs.chemrev.5b00456Agostini, A., Mondragón, L., Bernardos, A., Martínez-Máñez, R., Marcos, M. D., Sancenón, F., … Murguía, J. R. (2012). Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles. Angewandte Chemie International Edition, 51(42), 10556-10560. doi:10.1002/anie.201204663Agostini, A., Mondragón, L., Bernardos, A., Martínez-Máñez, R., Marcos, M. D., Sancenón, F., … Murguía, J. R. (2012). Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles. Angewandte Chemie, 124(42), 10708-10712. doi:10.1002/ange.201204663Agostini, A., Mondragón, L., Coll, C., Aznar, E., Marcos, M. D., Martínez-Máñez, R., … Amorós, P. (2012). Dual Enzyme-Triggered Controlled Release on Capped Nanometric Silica Mesoporous Supports. ChemistryOpen, 1(1), 17-20. doi:10.1002/open.201200003Aznar, E., Villalonga, R., Giménez, C., Sancenón, F., Marcos, M. D., Martínez-Máñez, R., … Amorós, P. (2013). Glucose-triggered release using enzyme-gated mesoporous silica nanoparticles. Chemical Communications, 49(57), 6391. doi:10.1039/c3cc42210kGiménez, C., de la Torre, C., Gorbe, M., Aznar, E., Sancenón, F., Murguía, J. R., … Amorós, P. (2015). Gated Mesoporous Silica Nanoparticles for the Controlled Delivery of Drugs in Cancer Cells. Langmuir, 31(12), 3753-3762. doi:10.1021/acs.langmuir.5b00139De la Torre, C., Casanova, I., Acosta, G., Coll, C., Moreno, M. J., Albericio, F., … Martínez-Máñez, R. (2014). Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells. Advanced Functional Materials, 25(5), 687-695. doi:10.1002/adfm.201403822De la Torre, C., Agostini, A., Mondragón, L., Orzáez, M., Sancenón, F., Martínez-Máñez, R., … Pérez-Payá, E. (2014). Temperature-controlled release by changes in the secondary structure of peptides anchored onto mesoporous silica supports. Chem. Commun., 50(24), 3184-3186. doi:10.1039/c3cc49421gAznar, E., Coll, C., Marcos, M. D., Martínez-Máñez, R., Sancenón, F., Soto, J., … Ruiz, E. (2009). Borate-Driven Gatelike Scaffolding Using Mesoporous Materials Functionalised with Saccharides. Chemistry - A European Journal, 15(28), 6877-6888. doi:10.1002/chem.200900090Bringas, E., Köysüren, Ö., Quach, D. V., Mahmoudi, M., Aznar, E., Roehling, J. D., … Stroeve, P. (2012). Triggered release in lipid bilayer-capped mesoporous silica nanoparticles containing SPION using an alternating magnetic field. Chemical Communications, 48(45), 5647. doi:10.1039/c2cc31563gSancenón, F., Pascual, L., Oroval, M., Aznar, E., & Martínez-Máñez, R. (2015). Gated Silica Mesoporous Materials in Sensing Applications. ChemistryOpen, 4(4), 418-437. doi:10.1002/open.201500053Oroval, M., Climent, E., Coll, C., Eritja, R., Aviñó, A., Marcos, M. D., … Amorós, P. (2013). An aptamer-gated silica mesoporous material for thrombin detection. Chemical Communications, 49(48), 5480. doi:10.1039/c3cc42157kPascual, L., Baroja, I., Aznar, E., Sancenón, F., Marcos, M. D., Murguía, J. R., … Martínez-Máñez, R. (2015). Oligonucleotide-capped mesoporous silica nanoparticles as DNA-responsive dye delivery systems for genomic DNA detection. Chemical Communications, 51(8), 1414-1416. doi:10.1039/c4cc08306gGiménez, C., Climent, E., Aznar, E., Martínez-Máñez, R., Sancenón, F., Marcos, M. D., … Rurack, K. (2014). Über den chemischen Informationsaustausch zwischen gesteuerten Nanopartikeln. Angewandte Chemie, 126(46), 12838-12843. doi:10.1002/ange.201405580Llopis-Lorente, A., Díez, P., Sánchez, A., Marcos, M. D., Sancenón, F., Martínez-Ruiz, P., … Martínez-Máñez, R. (2017). Interactive models of communication at the nanoscale using nanoparticles that talk to one another. Nature Communications, 8(1). doi:10.1038/ncomms15511Lu, J., Liong, M., Li, Z., Zink, J. I., & Tamanoi, F. (2010). Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. Small, 6(16), 1794-1805. doi:10.1002/smll.201000538Baeza, A., Manzano, M., Colilla, M., & Vallet-Regí, M. (2016). Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution. Biomaterials Science, 4(5), 803-813. doi:10.1039/c6bm00039hRosenholm, J. M., Sahlgren, C., & Lindén, M. (2010). Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles – opportunities & challenges. Nanoscale, 2(10), 1870. doi:10.1039/c0nr00156bPoh, S., Lin, J. B., & Panitch, A. (2015). Release of Anti-inflammatory Peptides from Thermosensitive Nanoparticles with Degradable Cross-Links Suppresses Pro-inflammatory Cytokine Production. Biomacromolecules, 16(4), 1191-1200. doi:10.1021/bm501849pPatel, A., Cholkar, K., & Mitra, A. K. (2014). Recent developments in protein and peptide parenteral delivery approaches. Therapeutic Delivery, 5(3), 337-365. doi:10.4155/tde.14.5Sung, B., Kim, C., & Kim, M.-H. (2015). Biodegradable colloidal microgels with tunable thermosensitive volume phase transitions for controllable drug delivery. Journal of Colloid and Interface Science, 450, 26-33. doi:10.1016/j.jcis.2015.02.068Witting, M., Molina, M., Obst, K., Plank, R., Eckl, K. M., Hennies, H. C., … Hedtrich, S. (2015). Thermosensitive dendritic polyglycerol-based nanogels for cutaneous delivery of biomacromolecules. Nanomedicine: Nanotechnology, Biology and Medicine, 11(5), 1179-1187. doi:10.1016/j.nano.2015.02.017Yu, E., Galiana, I., Martínez-Máñez, R., Stroeve, P., Marcos, M. D., Aznar, E., … Amorós, P. (2015). Poly(N-isopropylacrylamide)-gated Fe3O4/SiO2 core shell nanoparticles with expanded mesoporous structures for the temperature triggered release of lysozyme. Colloids and Surfaces B: Biointerfaces, 135, 652-660. doi:10.1016/j.colsurfb.2015.06.048Braun, K., Pochert, A., Lindén, M., Davoudi, M., Schmidtchen, A., Nordström, R., & Malmsten, M. (2016). Membrane interactions of mesoporous silica nanoparticles as carriers of antimicrobial peptides. Journal of Colloid and Interface Science, 475, 161-170. doi:10.1016/j.jcis.2016.05.002Zhou, C., Li, P., Qi, X., Sharif, A. R. M., Poon, Y. F., Cao, Y., … Chan-Park, M. B. (2011). A photopolymerized antimicrobial hydrogel coating derived from epsilon-poly-l-lysine. Biomaterials, 32(11), 2704-2712. doi:10.1016/j.biomaterials.2010.12.040SHIH, I., SHEN, M., & VAN, Y. (2006). Microbial synthesis of poly(ε-lysine) and its various applications. Bioresource Technology, 97(9), 1148-1159. doi:10.1016/j.biortech.2004.08.012Cabrera, S., El Haskouri, J., Guillem, C., Latorre, J., Beltrán-Porter, A., Beltrán-Porter, D., … Amorós *, P. (2000). Generalised syntheses of ordered mesoporous oxides: the atrane route. Solid State Sciences, 2(4), 405-420. doi:10.1016/s1293-2558(00)00152-7Mondragón, L., Mas, N., Ferragud, V., de la Torre, C., Agostini, A., Martínez-Máñez, R., … Orzáez, M. (2014). Enzyme-Responsive Intracellular-Controlled Release Using Silica Mesoporous Nanoparticles Capped with ε-Poly-L-lysine. Chemistry - A European Journal, 20(18), 5271-5281. doi:10.1002/chem.201400148Greenfield, N. J. (2006). Using circular dichroism spectra to estimate protein secondary structure. Nature Protocols, 1(6), 2876-2890. doi:10.1038/nprot.2006.202Mickan, A., Sarko, D., Haberkorn, U., & Mier, W. (2014). Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics. Current Pharmaceutical Biotechnology, 15(3), 200-209. doi:10.2174/13892010150314082210181

Estimating stable isotope turnover rates of epidermal mucus and dorsal muscle for an omnivorous fish using a diet-switch experiment

© 2018, The Author(s). Stable isotope (SI) analysis studies rely on knowledge of isotopic turnover rates and trophic-step discrimination factors. Epidermal mucus (‘mucus’) potentially provides an alternative SI ‘tissue’ to dorsal muscle that can be collected non-invasively and non-destructively. Here, a diet-switch experiment using the omnivorous fish Cyprinus carpio and plant- and fish-based formulated feeds compared SI data between mucus and muscle, including their isotopic discrimination factors and turnover rates (as functions of time T and mass G, at isotopic half-life (50) and equilibrium (95)). Mucus isotope data differed significantly and predictively from muscle data. The fastest δ13C turnover rate was for mucus in fish on the plant-based diet (T50: 17 days, T95: 74 days; G50: 1.08(BM), G95: 1.40(BM)). Muscle turnover rates were longer for the same fish (T50: 44 days, T95: 190 days; G50: 1.13(BM), G95: 1.68(BM)). Longer half-lives resulted in both tissues from the fish-based diet. δ13C discrimination factors varied by diet and tissue (plant-based: 3.11–3.28‰; fishmeal: 1.28–2.13‰). Mucus SI data did not differ between live and frozen fish. These results suggest that mucus SI half-lives provide comparable data to muscle, and can be used as a non-destructive alternative tissue in fish-based SI studies

Activated Human CD4+CD45RO+ Memory T-Cells Indirectly Inhibit NLRP3 Inflammasome Activation through Downregulation of P2X7R Signalling

Inflammasomes are multi-protein complexes that control the production of pro-inflammatory cytokines such as IL-1β. Inflammasomes play an important role in the control of immunity to tumors and infections, and also in autoimmune diseases, but the mechanisms controlling the activation of human inflammasomes are largely unknown. We found that human activated CD4+CD45RO+ memory T-cells specifically suppress P2X7R-mediated NLRP3 inflammasome activation, without affecting P2X7R-independent NLRP3 or NLRP1 inflammasome activation. The concomitant increase in pro-IL-1β production induced by activated memory T-cells concealed this effect. Priming with IFNβ decreased pro-IL-1β production in addition to NLRP3 inflammasome inhibition and thus unmasked the inhibitory effect on NLRP3 inflammasome activation. IFNβ suppresses NLRP3 inflammasome activation through an indirect mechanism involving decreased P2X7R signaling. The inhibition of pro-IL-1β production and suppression of NLRP3 inflammasome activation by IFNβ-primed human CD4+CD45RO+ memory T-cells is partly mediated by soluble FasL and is associated with down-regulated P2X7R mRNA expression and reduced response to ATP in monocytes. CD4+CD45RO+ memory T-cells from multiple sclerosis (MS) patients showed a reduced ability to suppress NLRP3 inflammasome activation, however their suppressive ability was recovered following in vivo treatment with IFNβ. Thus, our data demonstrate that human P2X7R-mediated NLRP3 inflammasome activation is regulated by activated CD4+CD45RO+ memory T cells, and provide new information on the mechanisms mediating the therapeutic effects of IFNβ in MS

Modulation of the expression of components of the stress response by dietary arachidonic acid in European sea bass (Dicentrarchus labrax) larvae

This study reports for the first time in European sea bass, Dicentrarchus labrax (L.), larvae, the effect of different levels of dietary arachidonic acid (ARA; 20:4n-6) on the expression of genes related to the fish stress response. Copies of mRNA from genes related to steroidogenesis (StAR (steroidogenic acute regulatory protein), c-Fos, and CYP11β (11β- hydroxylase gene)), glucocorticoid receptor complex (GR (glucorticoid receptor) and HSP (heat shock proteins) 70 and 90) and antioxidative stress (catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPX)) were quantified. Eighteen day-old larvae were fed for 14 days with three experimental diets with increasing levels of ARA (0.3, 0.6 and 1.2% d.w.) and similar levels of docosahexaenoic (DHA; 22:6n-3) and eicosapentaenoic (EPA; 20:5n-3) acids (5 and 3%, respectively). The quantification of stress-related genes transcripts was conducted by One-Step TaqMan real time RT-PCR with the standard curve method (absolute quantification). Increase dietary levels of ARA induced a significantly (p<0.05) down-regulation of genes related to cortisol synthesis, such as StAR and CYP11β and up-regulated genes related to glucocorticoid receptor complex, such as HSP70 and GR. No effects were observed on antioxidant enzymes gene expression. These results revealed the regulatory role of dietary ARA on the expression of stress-related genes in European sea bass larvae

Site-Specific and Time-Dependent Activation of the Endocannabinoid System after Transection of Long-Range Projections

Background: After focal neuronal injury the endocannabinioid system becomes activated and protects or harms neurons depending on cannabinoid derivates and receptor subtypes. Endocannabinoids (eCBs) play a central role in controlling local responses and influencing neural plasticity and survival. However, little is known about the functional relevance of eCBs in long-range projection damage as observed in stroke or spinal cord injury (SCI). Methods: In rat organotypic entorhino-hippocampal slice cultures (OHSC) as a relevant and suitable model for investigating projection fibers in the CNS we performed perforant pathway transection (PPT) and subsequently analyzed the spatial and temporal dynamics of eCB levels. This approach allows proper distinction of responses in originating neurons (entorhinal cortex), areas of deafferentiation/anterograde axonal degeneration (dentate gyrus) and putative changes in more distant but synaptically connected subfields (cornu ammonis (CA) 1 region). Results: Using LC-MS/MS, we measured a strong increase in arachidonoylethanolamide (AEA), oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) levels in the denervation zone (dentate gyrus) 24 hours post lesion (hpl), whereas entorhinal cortex and CA1 region exhibited little if any changes. NAPE-PLD, responsible for biosynthesis of eCBs, was increased early, whereas FAAH, a catabolizing enzyme, was up-regulated 48hpl. Conclusion: Neuronal damage as assessed by transection of long-range projections apparently provides a strong time-dependent and area-confined signal for de novo synthesis of eCB, presumably to restrict neuronal damage. The present data underlines the importance of activation of the eCB system in CNS pathologies and identifies a novel site-specific intrinsic regulation of eCBs after long-range projection damage

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden